Infectious Disease Testing Surges to $29B: Kalorama Report Highlights Molecular Breakthroughs and Point-of-Care Growth in IVD Market

 ARLINGTON, Va., June 17, 2025 /PRNewswire/ -- Kalorama Information, a leading authority in healthcare market intelligence, has released the latest edition of its bimonthly publication, In Vitro Diagnostics Business Outlook. Now in its fourth year, the most recent issue is a comprehensive market briefing offering exclusive insights into the evolving landscape of infectious disease testing—one of the most dynamic sectors within the global in vitro diagnostics (IVD) market. Previous issues have covered key IVD topics including cardiac biomarkers, glucose testing, point-of-care testing, blood screening, clinical chemistry, molecular HLA testing, and more.

According to the latest issue, the infectious disease testing market reached an estimated $29 billion in 2024, with COVID-19 testing accounting for 18% of total revenue, even as demand declines post-pandemic. Non-COVID point-of-care (POC) testing continued its upward trajectory, increasing by mid-single digits, and the segment remains a critical driver of diagnostic innovation globally.

"The infectious disease testing market is highly concentrated in North American and European markets, with a combined share exceeding three-quarters of the global market," said Daniel Granderson, Senior Editor at Kalorama Information. "However, distribution is slowly shifting as emerging markets ramp up adoption of molecular platforms and POC innovations."

The report highlights the growing impact of next-generation technologies, including alternative PCR methods, microarrays, NGS, and mass spectrometry. Instrument-automated analysis and miniaturized platforms are enabling broader deployment across physician offices, mobile health clinics, and even home settings—marking a transformational shift in test accessibility.

Other key insights from this edition:

• Molecular diagnostics remain concentrated in developed countries but show new growth in Latin America, Southeast Asia, and Africa.
  
  
• Point-of-care testing is increasingly pivoting to non-COVID applications, such as respiratory panels, STIs, and antimicrobial resistance surveillance.
  
  
• Investment, M&A, and R&D activity remain robust across diagnostic segments, as companies reorient toward long-term growth drivers beyond pandemic response.

A Strategic Resource for Healthcare Decision-Makers

In Vitro Diagnostics Business Outlook delivers six issues annually, each exploring a high-value IVD market segment. It is designed for:

• Corporate strategy teams seeking growth forecasts and pipeline planning data
  
  
• R&D and innovation leads tracking platform adoption and market shifts
  
  
• Investors and financial analysts evaluating diagnostic business models and M&A targets
  
  
• Clinical lab leaders and health policy experts seeking diagnostic utilization trends and access insights

Each issue includes:

• Market forecasts, growth rates, and share analysis
  
  
• Company and product profiles
  
  
• M&A and partnership tracking
  
  
• Geographic and regulatory trends
  
  
• Expert commentary and exclusive news analysis

Order Now

The full report can be purchased at:
https://kaloramainformation.com/product/in-vitro-diagnostics-business-outlook-2025-6-issues/

For purchase or custom consultation, contact:
Sheri Davie, Sales Director
sheri.davie@scienceandmedicinegroup.com

About Kalorama Information 

Kalorama Information, part of Science and Medicine Group Inc., is a trusted publisher of market research exclusively focused on the healthcare industry. For over 25 years, Kalorama has delivered accurate, timely, and strategic intelligence to leaders in biotechnology, clinical diagnostics, in vitro diagnostics (IVD), pharmaceuticals, medical devices, and broader healthcare sectors. 

Originally launched in 1998, Kalorama Information quickly established itself as a premier source of insight into U.S. and global medical markets. Today, Kalorama remains a leading authority on healthcare market dynamics, with a particular emphasis on IVD. 

Kalorama is best known for its flagship title, The Worldwide Market for In Vitro Diagnostic Tests, an internationally recognized benchmark in the diagnostics field. Other reports published throughout the year cover these and other healthcare topics in greater detail. Our innovative approach to research, combined with deep industry expertise, has made Kalorama a go-to resource for top healthcare companies, strategic planners, investors, and media seeking authoritative market data and trends. 

With a singular focus on healthcare, Kalorama continues to shape informed decision-making across the industry through comprehensive, evidence-based analysis. 

Kalorama also works in coordination with other Science and Medicine Group brands, including BioInformatics, which focuses on life science markets and marketing, SDi, the leading source of information on the laboratory life science and analytical instrumentation industry and publisher of IBO, its twice-monthly newsletter, and IMV, which publishes reports and data on the medical imaging and clinical markets. 

For more information about Kalorama Information and other services offered by Science and Medicine Group, please visit our website. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/infectious-disease-testing-surges-to-29b-kalorama-report-highlights-molecular-breakthroughs-and-point-of-care-growth-in-ivd-market-302484182.html

SOURCE Kalorama Information